{"id":"flovent-500mcg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"ritonavir","action":"Avoid","effect":"Significantly increases plasma fluticasone propionate exposure, resulting in reduced serum cortisol concentrations and potential systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression."},{"drug":"ketoconazole","action":"Avoid","effect":"Increases plasma fluticasone propionate exposure by 1.9-fold and decreases plasma cortisol AUC by 45%, but has no effect on urinary excretion of cortisol."}],"commonSideEffects":[],"contraindications":["Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required","Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate"],"specialPopulations":{"Pregnancy":"There are insufficient data on the use of FLOVENT DISKUS in pregnant women. In animals, teratogenicity characteristic of corticosteroids, decreased fetal body weight, and/or skeletal variations in rats, mice, and rabbits were observed with subcutaneously administered maternal toxic doses of fluticasone propionate less than the maximum recommended human daily inhaled dose (MRHDID) on a mcg/m² basis. However, fluticasone propionate administered via inhalation to rats decreased fetal body weight, but did not induce teratogenicity at a maternal toxic dose less than the MRHDID on a mcg/m² basis.","Geriatric use":"","Paediatric use":"The safety and effectiveness of FLOVENT DISKUS in children aged 4 years and older have been established. The safety and effectiveness of FLOVENT DISKUS in children younger than 4 years have not been established. Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients.","Renal impairment":"","Hepatic impairment":"Monitor patients for signs of increased drug exposure."}},"trials":[],"_chembl":null,"aliases":["FP 500"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$3.2668/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,192","description":"FLOVENT 100 MCG DISKUS","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLOVENT 500mcg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:53:20.799387+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:53:27.203570+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:53:20.867642+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLOVENT 500mcg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:53:27.547366+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:53:28.626006+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1473/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:53:28.281110+00:00"}},"offLabel":[],"timeline":[{"date":"1987-01-01","type":"positive","milestone":"Discovery of Fluticasone Propionate","regulator":"none"},{"date":"1990-06-01","type":"positive","milestone":"IND Submission for Fluticasone Propionate","regulator":"FDA"},{"date":"1991-03-01","type":"positive","milestone":"Phase 1 Clinical Trials Begin","regulator":"none"},{"date":"1992-09-01","type":"positive","milestone":"Phase 2 Clinical Trials Begin","regulator":"none"},{"date":"1994-05-01","type":"positive","milestone":"Phase 3 Clinical Trials Begin","regulator":"none"},{"date":"1996-08-01","type":"positive","milestone":"FDA Approval for Fluticasone Propionate (FLOVENT 500mcg)","regulator":"FDA"},{"date":"1997-12-01","type":"positive","milestone":"EMA Approval for Fluticasone Propionate (FLOVENT 500mcg)","regulator":"EMA"},{"date":"2001-04-01","type":"positive","milestone":"Label Expansion for Pediatric Use","regulator":"FDA"},{"date":"2008-01-01","type":"neutral","milestone":"Patent Expiry for Fluticasone Propionate","regulator":"none"}],"_dailymed":null,"aiSummary":"FLOVENT 500mcg is a glucocorticoid receptor agonist, classified as a small molecule in the agonist drug class. It is used to treat conditions such as asthma and chronic obstructive pulmonary disease, as indicated by clinical trials registered on ClinicalTrials.gov.","ecosystem":[],"mechanism":{"target":"Glucocorticoid receptor (GR)","novelty":"best-in-class","modality":"small molecule","drugClass":"Inhaled corticosteroid (ICS)","explanation":"","oneSentence":"","technicalDetail":"Fluticasone propionate demonstrates in vitro glucocorticoid receptor binding affinity substantially exceeding comparator corticosteroids, confirmed by McKenzie vasoconstrictor assay data in humans. The trifluorinated structure enhances lipophilicity and receptor selectivity, promoting lung tissue retention and local anti-inflammatory activity. Onset of clinical benefit requires 1-2 weeks due to gradual suppression of inflammatory cell recruitment and mediator production, with asthma stability persisting several days post-discontinuation."},"_scrapedAt":"2026-03-27T23:30:10.640Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"$265.85","peakSalesEstimate":"Not publicly reported"},"references":[],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:53:29.943773+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Advair Diskus","company":"GlaxoSmithKline","advantage":"Combines a long-acting beta2-adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) for better asthma control."},{"name":"Albuterol","company":"Various","advantage":"Rapid-acting bronchodilator for quick relief of asthma symptoms."},{"name":"Symbicort","company":"AstraZeneca","advantage":"Combines a LABA and an ICS for maintenance treatment of asthma and COPD."},{"name":"Singulair","company":"Merck & Co.","advantage":"Leukotriene receptor antagonist that helps reduce inflammation and bronchoconstriction."},{"name":"Montelukast","company":"Merck & Co.","advantage":"Leukotriene receptor antagonist that helps reduce inflammation and bronchoconstriction."},{"name":"Budesonide","company":"Various","advantage":"Inhaled corticosteroid for reducing inflammation in the airways."}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01966692","phase":"PHASE1","title":"Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-11","conditions":"Asthma","enrollment":24},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT02972476","phase":"PHASE4","title":"Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT03751202","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-11-20","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT01342913","phase":"PHASE3","title":"A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":528},{"nctId":"NCT01475721","phase":"PHASE4","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-18","conditions":"Asthma","enrollment":11751},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT00603746","phase":"PHASE2","title":"A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-01","conditions":"Asthma","enrollment":627},{"nctId":"NCT00927758","phase":"PHASE2","title":"Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair","status":"COMPLETED","sponsor":"Sandoz","startDate":"2009-06","conditions":"Asthma","enrollment":105},{"nctId":"NCT00361959","phase":"PHASE4","title":"SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1270},{"nctId":"NCT00358358","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease Endpoints Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":163},{"nctId":"NCT00549146","phase":"PHASE3","title":"Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":290},{"nctId":"NCT00268216","phase":"PHASE3","title":"Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6228},{"nctId":"NCT01498653","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT00268177","phase":"PHASE3","title":"Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":130},{"nctId":"NCT00920543","phase":"PHASE4","title":"GSK BHR Study (Sont)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-02","conditions":"Asthma","enrollment":464},{"nctId":"NCT01324362","phase":"PHASE4","title":"GSK BHR Study (Sont - Second Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Asthma","enrollment":446},{"nctId":"NCT01868113","phase":"PHASE3","title":"Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial","status":"COMPLETED","sponsor":"Makerere University","startDate":"2012-12","conditions":"Bacterial Pneumonia, Viral Pneumonia, Acute Asthma","enrollment":1010},{"nctId":"NCT00480649","phase":"PHASE4","title":"Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01","conditions":"Asthma","enrollment":424},{"nctId":"NCT01364519","phase":"PHASE1","title":"A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17},{"nctId":"NCT00379028","phase":"PHASE4","title":"Airway Clearance Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT00440687","phase":"PHASE4","title":"Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2001-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":256}],"_emaApprovals":[{"date":"","name":"FLOVENT 500mcg","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"A-S Medication Solutions","location":"","operator":"A-S Medication Solutions"}],"molecularData":{"oral":false,"chemblId":"CHEMBL1473","moleculeType":"Small molecule","molecularWeight":"500.58"},"_patentsChecked":true,"_warningLetters":[{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1473"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"1996-present","companyName":"GSK","relationship":"Originator"}],"pharmacokinetics":{"source":"FDA clinical pharmacology","halfLife":"7.8 hours","bioavailability":""},"publicationCount":2,"therapeuticAreas":["Respiratory"],"biosimilarFilings":[],"recentPublications":[{"date":"2008 Oct 8","pmid":"18843646","title":"Fluticasone at different doses for chronic asthma in adults and children.","journal":"The Cochrane database of systematic reviews"},{"date":"2004 Nov","pmid":"15526804","title":"Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.","journal":"Respiratory medicine"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"FLOVENT 500mcg","genericName":"FLOVENT 500mcg","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:53:29.943773+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}